RxDoctor Payments Data

Douglas Swartz, MD

Urology · Jacksonville, FLNPI 1144361908

Payments from drug & device makers

$117,507in general payments, 2019–2025

Across 160 payments — averaging $734.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SRS Medical Systems, Inc.$110K
  • Bayer$1K
  • Blue Earth Diagnostics$1K
  • KARL Storz Endoscopy-america$990
  • Boston Scientific$596
  • Medtronic$594
  • plus $4K from 30 others

What the payments were for

  • Consulting fees$111,43595%
  • Travel & lodging$5210%
  • Food & beverage$4,2484%
  • Education$3140%
  • Gifts$9901%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$117,507 in reported general payments places this provider in the 90th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$574,300
Medicare patients
841
Services billed
12,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide140$2,162,030
ErleadaApalutamide26$400,898
NubeqaDarolutamide27$355,920
OrgovyxRelugolix93$246,183
MyrbetriqMirabegron74$53,939
GemtesaVibegron55$43,619
Silodosin355$27,478
Tamsulosin Hcl744$10,186
Solifenacin Succinate268$10,136
Testosterone51$8,711
Finasteride361$5,534
Ibandronate Sodium82$2,333
Desmopressin Acetate40$2,038
Doxazosin Mesylate62$1,426
Potassium Citrate ErPotassium Citrate13$1,363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$161$2,215,969214 claims
Johnson & JohnsonErleada$422$400,89826 claims
BayerNubeqa$1,130$355,92027 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$35$289,802148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 urology providers in Florida.

Other urology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →